Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 35, 26 April 2024
Open
Access | Article
Aducanumab: The controversial drug for Alzhiemer’s Disease
* Author to whom correspondence should be addressed.
Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by a gradual and irreversible decline in cognitive function. The underlying pathology involves the accumulation of amyloid beta, a protein implicated in the development and progression of the illness. Aducanumab is a type of human monoclonal antibody that exhibits preferential immunoreactivity towards both soluble and insoluble aggregates of Amyloid Beta (Aβ). Two phase 3 studies, namely EMERGE and ENGAGE, were conducted to evaluate the efficacy of aducanumab in individuals with early Alzheimer’s disease. These studies were designed identically, randomized, and double-blind in nature. Both trials were suspended early with the ineffective results shown in interim analysis for futility. Aducanumab was reassessed and met the primary and secondary clinical endpoints in EMERGE, but remains ineffective in ENGAGE. Reduction of Aβ plaques was observed in the high-dose group (10 mg/kg), showing a dose- and time-dependent pattern. The primary safety concern with Aducanumab is amyloid-related imaging abnormalities (ARIA), particularly in ApoEε4 carriers. Aducanumab is a new therapeutic strategy for AD, providing new treatment with disease-modifying potential. This paper evaluated the pharmacology, mechanism, clinical studies, and safety assessment of aducanumab. This research aims to provide a reference for the understanding of Aducanumab’s current research status and results.
Keywords
Aducanumab, Alzheimer’s Disease, Amyloid beta, Clinical trials, Monoclonal antibody
References
1. Jack Jr, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., ... & Silverberg, N. (2018). NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia, 14(4), 535-562.
2. Hardy, J. A., & Higgins, G. A. (1992). Alzheimer’s disease: the amyloid cascade hypothesis. Science, 256(5054), 184-185.
3. Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO molecular medicine, 8(6), 595-608.
4. Prince, M., Wimo, A., Guerchet, M., Ali, G. C., Wu, Y. T., & Prina, M. (2015). World Alzheimer report 2015. The global impact of dementia: an analysis of prevalence, incidence, cost and trends (Doctoral dissertation, Alzheimer’s disease international).
5. Lane, C. A., Hardy, J., & Schott, J. M. (2018). Alzheimer’s disease. European journal of neurology, 25(1), 59-70.
6. YU, L. (2020). Preliminary evaluation of common experimental animal models for Alzheimer’s disease and mild cognitive impairment. Chinese Pharmacological Bulletin, 1-5.
7. Budd Haeberlein, S., Aisen, P. S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., ... & Sandrock, (2022). Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. The journal of prevention of Alzheimer’s disease, 9(2), 197-210.
8. Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., ... & Sandrock, A. (2016). The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature, 537(7618), 50-56.
9. Liu, E., Schmidt, M. E., Margolin, R., Sperling, R., Koeppe, R., Mason, N. S., ... & Brashear, H. R. (2015). Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology, 85(8), 692-700.
10. Salloway, S., Honigberg, L. A., Cho, W., Ward, M., Friesenhahn, M., Brunstein, F., ... & Paul, R. (2018). Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE). Alzheimer’s research & therapy, 10(1), 1-13.
11. Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu-Seifert, H., ... & Demattos, R. (2016). Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer’s disease patients. Alzheimer’s & Dementia, 12(2), 110-120.
12. Swanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y., ... & Cummings, J. L. (2021). A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimer’s research & therapy, 13, 1-14.
13. Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., ... & Skovronsky, D. M. (2021). Donanemab in early Alzheimer’s disease. New England Journal of Medicine, 384(18), 1691-1704.
14. Gamage, K. K., & Kumar, S. (2017). Aducanumab therapy ameliorates calcium overload in a mouse model of Alzheimer’s disease. Journal of Neuroscience, 37(17), 4430-4432.
15. Jarosz-Griffiths, H. H., Noble, E., Rushworth, J. V., & Hooper, N. M. (2016). Amyloid-β receptors: the good, the bad, and the prion protein. Journal of biological chemistry, 291(7), 3174-3183.
16. Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., ... & Phelps, C. H. (2011). The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & dementia, 7(3), 270-279.
17. McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack Jr, C. R., Kawas, C. H., ... & Phelps, C. H. (2011). The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & dementia, 7(3), 263-269.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Modern Medicine and Global Health
- ISBN (Print)
- 978-1-83558-395-1
- ISBN (Online)
- 978-1-83558-396-8
- Published Date
- 26 April 2024
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/35/20240832
- Copyright
- 26 April 2024
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited